Danaher Analysts Cut Their Forecasts After Downbeat Earnings
1. DHR's Q4 EPS of $2.14 missed expectations of $2.16. 2. Quarterly sales increased by 2%, exceeding consensus of $6.42 billion. 3. Biotechnology and Life Sciences segments grew, while Diagnostics segment fell 3%. 4. Analysts lowered price targets; Barclays to $240, Wells Fargo to $240. 5. DHR shares dropped 9.7% to $223.73 following earnings results.